IFIH1 and clinically amyopathic dermatomyositis: Previous reports have indicated that, depending on the cohort (14–22), 23–100% of anti-MDA5 antibody-positive patients develop CADM and have shown that anti-MDA5 antibody-associated ILD rapidly progresses and has a poor prognosis (23).